Pulmonx Revises 2025 Revenue Target to $90M-$92M as International Growth Surges

Pulmonx Corporation has revised its 2025 revenue target to $90-92 million. The company's Q2 revenue was $23.9 million, driven by strong international growth, with revenue reaching $9.1 million. CEO Steven S. Williamson highlighted the international performance, stating it was a testament to the strength of the company's global footprint.

Pulmonx Corporation (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has revised its 2025 revenue target to $90-92 million. The company reported strong financial results for the second quarter of 2025, with worldwide revenue reaching $23.9 million, a 15% increase over the same period last year and a 13% increase on a constant currency basis [1].

The company's international revenue was $9.1 million, representing a 32% year-over-year growth and a 27% increase on a constant currency basis. This growth was driven by strong international performance, which CEO Steven S. Williamson highlighted as a testament to the company's global footprint. The U.S. revenue was $14.7 million, representing a 6% year-over-year growth [1].

Pulmonx's gross margin for the second quarter of 2025 was 72%, down from 74% in the same period last year. The company's operating expenses were $32.0 million, a 3% increase from the second quarter of 2024. The net loss for the second quarter of 2025 was $15.2 million, or $0.38 per share, compared to a net loss of $15.3 million, or $0.39 per share, for the same period in 2024 [1].

The company is expecting gross margin for the full year 2025 to be approximately 74% and total operating expenses for the full year 2025 to fall within the range of $128 million to $130 million. Pulmonx has also revised its full-year 2025 revenue guidance to be in the range of $90 million to $92 million, anticipating a trajectory slightly lower than its prior expectations of $96 million to $98 million [1].

Pulmonx is currently revising its full-year 2025 revenue guidance to reflect longer-than-expected revenue conversion from its U.S. initiatives. The company is seeing early signs of traction in its efforts to build a scalable ecosystem by improving patient identification, access, and engagement [1].

References:
[1] https://www.globenewswire.com/news-release/2025/07/30/3124425/0/en/Pulmonx-Reports-Second-Quarter-2025-Financial-Results.html